ESIDRIX
LOE ApproachingNDAORALTABLET
Approved
Feb 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ESIDRIX is an oral small-molecule tablet approved in 1959 by Novartis. The generic name and mechanism of action are not specified in available data. This is a legacy product with a long commercial history.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; expect team rightsizing and transition focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ESIDRIX has zero linked job openings, reflecting its LOE-approaching status. Career opportunities on this product are declining as the brand enters maintenance and transition phases.
Brand ManagerField Sales Representative
Worked on ESIDRIX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.